Table of ContentsView AllTable of ContentsUsesBefore TakingDosageSide EffectsWarnings and Interactions

Table of ContentsView All

View All

Table of Contents

Uses

Before Taking

Dosage

Side Effects

Warnings and Interactions

As such, it’s a first-line treatment for the excessive need to urinate andurinary incontinence—the inability to control bladder function—associated with OAB.

FG Trade / Getty Images

A woman with overactive bladder washing her hands in the bathroom, Gemtesa Vibegron

Gemtesa is indicated to treat OAB in adults. It is a new drug and has not yet been approved for off-label use. To be diagnosed with OAB, you must have at least two of the following symptoms:

Before Gemtesa can be prescribed, your healthcare provider will need to ensure you have OAB. Notably, this involves ruling out other disorders or diseases of the bladder. Typically, diagnosis involves the following:

Know What You’re TakingTalk to your healthcare provider about all medications, supplements, and vitamins that you currently take. While some drugs pose minor interaction risks, others may contraindicate use or prompt careful consideration of whether the pros of treatment outweigh the cons in your case.

Know What You’re Taking

Talk to your healthcare provider about all medications, supplements, and vitamins that you currently take. While some drugs pose minor interaction risks, others may contraindicate use or prompt careful consideration of whether the pros of treatment outweigh the cons in your case.

Precautions and Contraindications

As with any drug, Gemtesa may be dangerous to take under certain conditions. These include:

Other Beta-3 Agonists

Gemtesa is part of a broader family of pharmaceuticals that act on the beta-3 receptors, stimulating their activity. Though some of these drugs may be used for other reasons—including as an antidepressant or to treat irritable bowel syndrome—they’re mostly intended for use against OAB. These include:

Aside from Myrbetriq, which currently is available for use, the drugs in this list are still undergoing clinical trials; however, there is a great deal of research into their potential for treating OAB.

Gemtesa comes in a tablet form, with a strength of 75 milligrams (mg); one tablet per day is indicated for OAB. These pills are oval-shaped, light green, and have “V75” engraved on one side.

Modifications

While there are no modifications of Gemtesa in terms of dosage amounts, users can crush the tablet, mix it with about 15 milliliters (ml) of applesauce (a little over 1 tablespoon), and drink that with a glass of water.For some, this approach can make taking Gemtesa more palatable.

How to Take and Store

Taking Gemtesa is straightforward. It can be taken with or without food, and it’s best with a glass of water.As for storage of this drug, there are several things to keep in mind:

Cases of overdose haven’t yet been recorded. Contact your healthcare provider if you have taken more pills than directed, or if you are experiencing discomfort and severe side effects.

As with any drug, Gemtesa causes some side effects. These should be monitored, and you shouldn’t hesitate to let your healthcare provider know if you are experiencing any unusual symptoms.

Common

Common side effects of Gemtesa use are cause for concern if they’re disruptive and persistent. These include:

Severe

Only one severe side effect of Gemtesa has been recorded: urninary retention, or the inability to empty the bladder. Chances of this occurring increase if you take other medications for OAB or experiencebladder outlet obstruction (BOO).

Not being able to empty the bladder causes discomfort and can lead to infections, weakened urine flow, bladder stones, and kidney problems. If you’re not able to empty your bladder, be sure to call your healthcare provider as soon as possible and stop taking this medication.

When you’re taking Gemtesa, you’ll need to be aware of the following warnings and indications:

7 SourcesVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Huang C, Lin C, Lin A.Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting.Sci Rep. 2020;10(1). doi:10.1038/s41598-020-68170-4Urovant Sciences.Now approved: GEMTESA® (vibegron) 75 mg tablets. 2021.MedlinePlus.Overactive bladder: polyuria.Urology Care Foundation.Overactive bladder (OAB): symptoms, diagnosis & treatment. Urology Health.National Institute of Diabetes and Digestive and Kidney Diseases.Cystoscopy & ureteroscopy.U.S. Food and Drug Administration.Gemtesa (vibegron) tablets, for oral use.Schena G, Caplan M.Everything you always wanted to know about β3-AR * (* but were afraid to ask).Cells. 2019;8(4):357. doi:10.3390/cells8040357

7 Sources

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Huang C, Lin C, Lin A.Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting.Sci Rep. 2020;10(1). doi:10.1038/s41598-020-68170-4Urovant Sciences.Now approved: GEMTESA® (vibegron) 75 mg tablets. 2021.MedlinePlus.Overactive bladder: polyuria.Urology Care Foundation.Overactive bladder (OAB): symptoms, diagnosis & treatment. Urology Health.National Institute of Diabetes and Digestive and Kidney Diseases.Cystoscopy & ureteroscopy.U.S. Food and Drug Administration.Gemtesa (vibegron) tablets, for oral use.Schena G, Caplan M.Everything you always wanted to know about β3-AR * (* but were afraid to ask).Cells. 2019;8(4):357. doi:10.3390/cells8040357

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

Huang C, Lin C, Lin A.Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting.Sci Rep. 2020;10(1). doi:10.1038/s41598-020-68170-4Urovant Sciences.Now approved: GEMTESA® (vibegron) 75 mg tablets. 2021.MedlinePlus.Overactive bladder: polyuria.Urology Care Foundation.Overactive bladder (OAB): symptoms, diagnosis & treatment. Urology Health.National Institute of Diabetes and Digestive and Kidney Diseases.Cystoscopy & ureteroscopy.U.S. Food and Drug Administration.Gemtesa (vibegron) tablets, for oral use.Schena G, Caplan M.Everything you always wanted to know about β3-AR * (* but were afraid to ask).Cells. 2019;8(4):357. doi:10.3390/cells8040357

Huang C, Lin C, Lin A.Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting.Sci Rep. 2020;10(1). doi:10.1038/s41598-020-68170-4

Urovant Sciences.Now approved: GEMTESA® (vibegron) 75 mg tablets. 2021.

MedlinePlus.Overactive bladder: polyuria.

Urology Care Foundation.Overactive bladder (OAB): symptoms, diagnosis & treatment. Urology Health.

National Institute of Diabetes and Digestive and Kidney Diseases.Cystoscopy & ureteroscopy.

U.S. Food and Drug Administration.Gemtesa (vibegron) tablets, for oral use.

Schena G, Caplan M.Everything you always wanted to know about β3-AR * (* but were afraid to ask).Cells. 2019;8(4):357. doi:10.3390/cells8040357

Meet Our Medical Expert Board

Share Feedback

Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit

Was this page helpful?

Thanks for your feedback!

What is your feedback?OtherHelpfulReport an ErrorSubmit

What is your feedback?